Companies: Eli Lilly, Ascidian, Roche
LLY
Eli Lilly and Ascidian Therapeutics Forge RNA Exon Editing Alliance for Genetic Kidney Diseases
Eli Lilly has entered a significant research collaboration with Ascidian Therapeutics, aiming to develop novel RNA exon editing therapeutics for genetic kidney diseases. The deal highlights the growing interest in RNA-based therapies and Ascidian's innovative exon editing technology.
Executive Summary
- Eli Lilly and Ascidian Therapeutics have signed a research collaboration to discover and develop RNA exon editing therapeutics for genetic kidney diseases, combining Ascidian's RNA exon editing product engine with Lilly's genetic medicines and renal disease expertise.
- Ascidian's exon editing takes place at the RNA level, limiting the risk of off-target DNA edits or expression of transgenes in inappropriate cell types.
- The approach enables the replacement of exons at the kilobase scale, addresses multiple mutations with a single therapy, and maintains native gene expression without changes to DNA.
- Ascidian has also entered a separate RNA exon editing collaboration with Roche targeting neurological diseases.
Market Impact
| Regulatory | low |
|---|---|
| Commercial | high |
| Competitive | high |
| Investment | high |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Eli Lilly and Ascidian Therapeutics Forge RNA Exon Editing Alliance for Genetic Kidney Diseases
Eli Lilly has entered a research collaboration with Ascidian Therapeutics to develop novel RNA exon editing therapeutics for genetic kidney diseases. The deal highlights growing interest in RNA-based therapies and Ascidian's innovative exon editing technology. Under the agreement, Lilly gains rights to discover and develop RNA exon editing therapeutics for genetic kidney diseases, combining Ascidian's RNA exon editing product engine with Lilly's genetic medicines and renal disease expertise.
Key Takeaways
- Eli Lilly and Ascidian Therapeutics have signed a research collaboration to discover and develop RNA exon editing therapeutics for genetic kidney diseases, combining Ascidian's RNA exon editing product engine with Lilly's genetic medicines and renal disease expertise.
- Ascidian's exon editing takes place at the RNA level, limiting the risk of off-target DNA edits or expression of transgenes in inappropriate cell types.
- The approach enables the replacement of exons at the kilobase scale, addresses multiple mutations with a single therapy, and maintains native gene expression without changes to DNA.
- Ascidian has also entered a separate RNA exon editing collaboration with Roche targeting neurological diseases.
The RNA Exon Editing Alliance
Eli Lilly and Ascidian Therapeutics have announced a research collaboration focused on genetic kidney diseases, granting Lilly rights to discover and develop RNA exon editing therapeutics using Ascidian's proprietary platform. The deal merges Ascidian's RNA exon editing engine with Lilly's established capabilities in genetic medicines and renal disease biology.
For Ascidian, the collaboration provides a major pharmaceutical partner with deep clinical development infrastructure. For Lilly, it represents a bet on a technology that could address the root cause of inherited kidney disorders without permanently altering the genome. The renal disease space has drawn growing industry interest, yet most approved therapies address symptoms or slow progression rather than correcting underlying genetic drivers.
How Does Ascidian's Exon Editing Technology Work?
Ascidian Therapeutics specializes in RNA exon editing, a technique that corrects disease-causing mutations by inducing trans-splicing between a synthetic RNA molecule and an endogenous pre-mRNA target. This process results in functionally restored mRNA and protein. According to a peer-reviewed overview published in Molecular Therapy Nucleic Acids, the approach enables the replacement of exons at the kilobase scale, addresses multiple mutations with a single therapy, and maintains native gene expression without changes to DNA.
A key differentiator: Ascidian's exon editing takes place at the RNA level, limiting the risk of off-target DNA edits or expression of transgenes in inappropriate cell types. For genes larger than 5 kb, RNA exon editors can be delivered in a single AAV vector because only mutated exons need to be replaced, sidestepping the packaging constraints that limit conventional gene replacement therapies.
Why Is Eli Lilly Expanding into Genetic Kidney Diseases?
For Eli Lilly, this collaboration represents a strategic move to bolster its capabilities in genetic medicines and expand into rare genetic kidney diseases, an area of significant unmet need. By partnering with Ascidian, Lilly gains access to a novel RNA-based therapeutic engine that complements its existing small molecule and biologic expertise.
The deal allows Lilly to explore a differentiated approach to treating conditions where conventional modalities have shown limited efficacy. It also signals Lilly's willingness to pursue platform-level partnerships in emerging therapeutic modalities, a strategy that diversifies pipeline risk while securing access to advanced science in the renal space.
What Does the Competitive Landscape Look Like?
The Lilly-Ascidian deal signals a growing trend of major pharmaceutical companies investing in RNA-based therapeutic technologies, including exon editing. Ascidian's prior collaboration with Roche for neurological targets demonstrates the broad applicability of its platform across therapeutic areas.
Roche and Ascidian entered a separate RNA exon editing collaboration targeting neurological diseases, combining Ascidian's RNA exon editing platform with Roche's next-generation CNS delivery capabilities. That deal was disclosed via press release from PR Newswire, underscoring the commercial interest RNA exon editing platforms have attracted from Big Pharma across multiple therapeutic areas.
For BD teams and investors, these partnerships underscore the increasing importance of RNA exon editing as a competitive modality in the gene therapy space. The fact that two major pharma companies have now secured rights to Ascidian's platform in different therapeutic areas suggests the technology has passed early validation thresholds. SEC filings for RNA-targeting biotechnology companies have also drawn heightened attention from institutional investors tracking the gene therapy sector.
What Should Industry Watchers Monitor Next?
Several milestones will determine whether this alliance delivers on its promise. First, the selection of specific genetic kidney disease targets will reveal the scope and ambition of the collaboration. Second, preclinical proof-of-concept data demonstrating efficient exon editing in renal tissue will be critical for investor confidence. Third, the timeline toward an IND filing will signal whether the partnership is progressing at a competitive pace relative to other genetic medicine programs in the renal space.
The deal also raises broader questions about how RNA exon editing will compete with CRISPR-based gene editing and antisense oligonucleotide approaches in the genetic disease arena. Each modality carries distinct risk-benefit profiles, and the clinical data emerging from programs like this one will ultimately determine which approaches gain traction with regulators and payers.
Frequently Asked Questions
What is the core of the Eli Lilly and Ascidian Therapeutics deal?
Eli Lilly and Ascidian Therapeutics have entered a research collaboration focused on developing RNA exon editing therapeutics for genetic kidney diseases. The deal combines Ascidian's RNA exon editing product engine with Lilly's genetic medicines and renal disease expertise.
What technology does Ascidian Therapeutics bring to the partnership?
Ascidian Therapeutics contributes its proprietary RNA exon editing product engine, which operates at the RNA level to correct genetic mutations. The technology induces trans-splicing between a synthetic RNA molecule and an endogenous pre-mRNA target, resulting in functionally restored mRNA and protein without altering the underlying DNA sequence.
What are the key benefits of Ascidian's RNA exon editing approach?
Ascidian's approach limits the risk of off-target DNA edits and corrects genetic mutations by replacing faulty RNA segments with functional ones. The method enables exon replacement at the kilobase scale and can address multiple mutations with a single therapy, all while maintaining native gene expression.
What other major collaborations has Ascidian Therapeutics been involved in?
Ascidian Therapeutics has also partnered with Roche on a deal focused on RNA exon editing therapeutics for neurological diseases. That collaboration combines Ascidian's platform with Roche's CNS delivery capabilities, demonstrating the broad therapeutic applicability of the exon editing technology.
How does RNA exon editing differ from traditional gene therapy?
Unlike conventional gene therapy, which introduces a functional copy of a gene into the genome, RNA exon editing corrects mutations at the RNA level through trans-splicing. This avoids permanent changes to DNA, reduces the risk of off-target genomic edits, and allows large genes to be addressed within a single AAV vector by replacing only the mutated exons rather than the entire gene.
Related profiles
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
